Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report

Fig. 2

Follow-up schematic diagram between September 2016 and July 2017. The top panel shows a PET/CT scan (column a) and a series of CT scans of the lung window and mediastinal window (columns bd) of the primary lesion, which decreased in size after crizotinib treatment targeting the EZR-ROS1 fusion protein (columns a and b). However, relapse was detected in April 2017 (column c), which was controlled with lorlatinib until now (column d). The bottom panel depicts the follow-up changes of serum CEA levels, which markedly decreased after crizotinib treatment, and increased in April 2017 after disease progression, showing a decreasing trend after lorlatinib treatment. CT, computed tomography; PET, positron emission tomography; CEA, carcinoembryonic antigen

Back to article page